-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Managing Toxicities of PI3K Inhibitors

Program: Education Program
Session: Managing Toxicities of Targeted Therapies in CLL
Hematology Disease Topics & Pathways:
Leukemia, Diseases, CLL, Adverse Events, B-Cell Lymphoma, Lymphoid Malignancies
Saturday, December 5, 2020, 1:55 PM-2:00 PM

Danielle M. Brander, MD

Duke Cancer Institute, Duke University, Durham, NC

Disclosures: Brander: NCCN: Other; Novartis: Consultancy, Other; Tolero: Research Funding; Pfizer: Consultancy, Other; Genentech: Consultancy, Honoraria, Other, Research Funding; Juno/Celgene/BMS: Other, Research Funding; MEI Pharma: Other, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Other, Research Funding; Novartis: Consultancy, Other; NCCN: Other; Verastem: Consultancy, Honoraria, Other, Research Funding; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; DTRM: Other, Research Funding; Teva: Consultancy, Honoraria; BeiGene: Other, Research Funding; AstraZeneca: Consultancy, Honoraria, Other, Research Funding; Ascentage: Other, Research Funding; ArQule: Consultancy, Other, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Tolero: Research Funding; Teva: Consultancy, Honoraria.

OffLabel Disclosure: As it pertains to toxicities of PI3K in development as monotherapy, or in combination, and/or trials look at intolerance to other agents

See more of: Managing Toxicities of Targeted Therapies in CLL
See more of: Education Program
<< Previous Presentation | Next Presentation